SALIENT IMAGING

Salient Imaging specializes in developing application software for ultrasound imaging systems. Their primary focus is on tools that improve vascular visualization, such as their product *Visualize:Vascular*, which aids in analyzing and interpreting blood vessels during ultrasound scans. These are not standalone hardware devices but software solutions integrated with existing ultrasound systems.

Salient Imaging is based in the United States, which means its devices fall under the jurisdiction of the FDA (U.S. Food and Drug Administration). Since their products are classified as Class II devices, they are subject to FDA’s moderate regulatory controls, including compliance with quality system regulations and post-market surveillance requirements. The U.S. origin also means their devices are listed in the FDA’s Unique Device Identifier (UDI) database for traceability.

Salient Imaging’s devices are included in the FDA’s Unique Device Identifier (UDI) database, which is a publicly accessible registry that tracks medical devices authorized for sale in the U.S. This database helps healthcare providers, regulators, and other stakeholders verify device details, such as manufacturer information, device identifiers, and regulatory classifications. The inclusion in this system is required for Class II devices in the U.S.

Salient Imaging’s products, including *Visualize:Vascular*, are classified as FDA Class II devices. This classification is determined by the FDA based on the level of risk associated with the device. Class II devices generally pose a moderate risk and require compliance with special controls (e.g., performance standards, labeling requirements) in addition to the general controls outlined in the FDA’s regulations. The classification ensures that these software applications for ultrasound imaging undergo appropriate scrutiny to maintain safety and effectiveness.